PNC Financial Services Group 13F Portfolio

The biggest buys are not single stocks but building blocks. The fund is telling you it wants systematic exposure to U.S. growth, quality tilts, and a deeper slice of the market cap spectrum.

Key conviction adds:

• IWF (iShares Russell 1000 Growth) is the headline add, with shares up +298.3% and value rising by about $1.13B. That is a clear statement: they want large-cap U.S. growth, but in a broad index, not packaged in idiosyncratic stock picks.
• VUG (Vanguard Growth) is up +496.1% in shares and roughly +$976.8M in value, reinforcing the same idea from a different sponsor. Two giant growth ETFs moving up together are not an accident.
• VO (Vanguard Mid-Cap) jumps +307.7% in shares and about +$584.7M in value, signaling a preference for the “middle of the market” where AI beneficiaries, industrial automation, and compounders live without mega-cap concentration.
• AVLV (Avantis U.S. Large Cap Value) adds about $499.9M, indicating they’re not pure growth chasers; they want factor diversification via value inside a rules-based wrapper.
• IDEV and IEMG, both increased with dollar adds of roughly $188.6M and $65.1M respectively, show growing comfort with international developed and emerging markets through low-cost cores.
• In fixed income, GOVT and AGG were both boosted, adding about $107.9M and $63.0M. That’s not a timing call on rates as much as it is a structural move to shore up the ballast behind a very equity-heavy, Lilly-heavy profile.

Even where they like stock-specific AI exposure — in names like Nvidia, Microsoft, and Meta — the position changes are modest. The real risk-on statement is that massive capital is going into scalable, liquid growth ETFs rather than more concentrated stock bets.

On the other side of the ledger, the funding sources are revealing. They’re not blowing out of equities; they’re upgrading which equities they own and how they package their themes.

The notable trims:

• AIQ (Global X Artificial Intelligence & Technology) is the single clearest reversal, with shares down -34.5% and an estimated -$614.9M cut. That looks like a conscious decision to abandon a narrow AI marketing label in favor of owning AI through broad growth indices and megacaps.
• IVV and QQQ are both gently reduced (IVV by -1.7%, about -$198.3M; QQQ by -3.0%, about -$64.8M). This smells like a shift away from cap-weight core S&P 500 and NASDAQ-100 into more tailored growth and factor exposures (IWF, VUG, AVLV) rather than a bearish call on U.S. equities.
• QUAL and DGRW, both quality/dividend-tilt ETFs, see meaningful trims (QUAL at -6.9%, DGRW at -5.1%). This suggests they’re willing to sacrifice some defensive factor exposure now that they have a giant defensive anchor in Eli Lilly plus more fixed income.
• In single names, they eased off Procter & Gamble (-7.3%, roughly -$82.8M), Exxon Mobil (-5.0%, about -$70.2M), and modestly reduced Johnson & Johnson, Merck, and consumer holdings like Home Depot. That’s a quiet de-emphasis of classic defensives and energy beta.
• Alphabet’s GOOGL line is cut by -2.2% (~$69.3M), even as the GOOG class is slightly increased, a housekeeping move that doesn’t alter the underlying thesis on the business.

Overall, the trims look more like a portfolio architecture decision — simplifying and rebalancing factor exposures — than a top-down market call.

On paper, this still looks like a health-care fund masquerading as a multi-asset manager. Health care, almost entirely through Eli Lilly plus big pharmas like Johnson & Johnson, AbbVie, and Merck, sits at 46.16% of the disclosed book versus 46.99% previously — a tiny drift down, but from a very elevated base.

Technology exposure is stable (13.43% now versus 13.68%), but the composition is telling: Nvidia and Broadcom remain large winners by performance, and Microsoft, Alphabet, and Meta are being managed around the edges rather than being used as primary risk levers. They’re letting tech ride, not leaning harder into it this quarter.

The real structural move sits in the “Unclassified” bucket, which is overwhelmingly ETFs. That slice rises from 30.94% to 32.38%, powered by large adds to IWF, VUG, VO, AVLV, IDEV, IEMG, and bond funds like GOVT, AGG, and IEF. Under the hood, that means more U.S. growth, more mid-caps, more international, and more duration.

Classical cyclicals and income areas are being nudged lower: finance edges down (2.43% to 2.34%), energy via Exxon falls (1.02% to 0.95%), and consumer exposure, including Procter & Gamble and Home Depot, ticks down slightly. Visa, mis-categorized here as real estate but functionally a payments/tech name, is gently trimmed as well.

Net-net, sector risk is still dominated by one health-care name and a tech cluster, but the ETF sleeve is quietly broadening the book’s economic footprint — more growth and mid-cap cyclicality on the one hand, more Treasuries and aggregate bonds on the other.

Put together, this quarter looks less like a hero call and more like a risk-system upgrade. With Eli Lilly up about 84.2% versus their average cost and swallowing 30.51% of the book, they are not in a hurry to shrink their winner — but they are clearly building the scaffolding around it.

Shifting from AIQ into IWF and VUG says they still buy the AI/growth story but don’t trust niche wrappers to express it. Loading up VO and AVLV shows a preference for diversified factor exposures where security selection risk is low and liquidity is high.

At the same time, incremental buying of GOVT, AGG, and IEF hints at an awareness that a portfolio this equity-heavy, and this concentrated in one pharma name, needs more ballast. They are not de-risking in the headline sense — equity beta is actually being reinforced — but the bond adds give them optionality if volatility returns.

Going forward, expect the direction of travel, not the destination, to matter. As long as Lilly remains intact at ~30% and tech stays around 13%, the main variable they can adjust quarter to quarter is the ETF architecture: how much growth versus value, how much mid-cap versus mega, how much U.S. versus international, and how much bonds sit underneath.

For allocators reading this tape, the message is straightforward: PNC is staying long growth and pharma, but it’s moving from story-driven slices to broad beta and factor blocks. The risk is concentrated in a few structural bets; the rest of the book is being engineered to make those bets survivable across cycles.